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Iron is essential for life, while also being potentially harmful. Therefore, its level is strictly monitored and complex pathways have
evolved to keep iron safely bound to transport or storage proteins, thereby maintaining homeostasis at the cellular and systemic
levels. These sequestration mechanisms ensure that mildly reactive oxygen species like anion superoxide and hydrogen peroxide,
which are continuously generated in cells living under aerobic conditions, keep their physiologic role in cell signalingwhile escaping
iron-catalyzed transformation in the highly toxic hydroxyl radical. In this review, we describe the multifaceted systems regulating
cellular and body iron homeostasis and discuss how altered iron balance may lead to oxidative damage in some pathophysiological
settings.
1. Introduction
In eukaryotes, oxygen utilization by the mitochondria,
NADPHoxidase enzymes, cytochromes, and so forth leads to
the generation of reactive oxygen species (ROS), unstable and
reactive molecules formed by one-electron transfers from a
redox donor tomolecular oxygen.Thefirst of such products is
anion superoxide (O
2
−), which can be converted to hydrogen
peroxide (H
2
O
2
) by superoxide dismutase enzymes. Metal-
catalyzed oxidation of H
2
O
2
can then originate hydroxyl
radicals (HO∙), themost reactive ROS. Redox balance, that is,
regulated production of ROS, is essential for normal cellular
physiology, as deregulation in the production of oxidative
species, that is, oxidative stress, causes DNA damage, lipid
peroxidation, and aberrant posttranslational modification of
proteins, thus leading to injury, cell death, and disease [1].
Conversely, accumulating evidence indicates that physiolog-
ical concentrations of ROS are necessary to support redox
signaling events that are involved in important physiological
functions and adaptive cell responses, such as chemotaxis,
hormone synthesis, immune response, cytoskeletal remod-
eling, and calcium homeostasis [2]. To be considered as
signaling biological messengers, ROS should meet precise
spatial and regulatory criteria; that is, they should be
produced enzymatically and their levels should be regulated
by intracellular molecular mechanisms [3, 4]. Therefore, O
2
−
andH
2
O
2
, particularlyH
2
O
2
that ismore stable thanO
2
− and
can cross membranes, are considered signaling molecules
because their levels under normal conditions remain under
a physiological threshold and their synthesis is enzymatically
regulated, whereas HO∙ is deemed to be a highly toxic reac-
tant leading to permanent modifications of target molecules
that can impact cellular function and life. In the cell, rapid
and efficient conversion of H
2
O
2
to HO∙ through the Fenton
reaction requires the presence of transition metals, that is,
copper and iron.While copper is amore efficient catalyst, iron
is much more abundant and thus it is the actual key player in
the so-called metal-catalyzed oxidative reactions [5].
While metal-dependent ROS production has histori-
cally been associated with necrosis, a form of passive cell
death characterized by dissolution of cellular structures, new
evidence suggests a role in regulated necrosis. In fact, a
form of regulated cell death, termed ferroptosis because it
requires iron, has been recently identified [6]. Interestingly,
ferroptosis is induced following inhibition of cystine import
and downstream glutathione synthesis, leading to the accu-
mulation of intracellular ROS and lipid peroxidation [7].
Further evidence for the role of iron-mediated disruption
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Figure 1: Dual role of ROS as signaling and toxic molecules, iron
tips the scale for damage. By triggering Fenton chemistry, increased
iron (Fe) availability may change the role of H
2
O
2
from a relatively
safe compound involved in cell signaling to a source of the highly
toxic HO∙.
of cellular redox homeostasis in ferroptosis was provided
by the essential regulatory function in ferroptotic cell death
of glutathione peroxidase [8], which is the only known
enzyme able to reduce phospholipid hydroperoxides and
thus one of the most important antioxidant enzymes, and
by the demonstration that transferrin-mediated iron import
is essential for ferroptosis [9]. Moreover, in hepatocellular
carcinoma cells, knockdown of H ferritin, one of the two
subunits that compose the iron storage protein ferritin,
promoted ferroptosis in response to classical inducers [10].
During the slow and long process of oxygen accumulation
that led to the present 20.9% atmospheric oxygen content
initiated about 1.5 billion years ago by photosynthesizing
cyanobacteria, all life forms evolved mechanisms to exploit
the chemical reactivity of iron for efficient aerobic reac-
tions. Indeed, the number of iron-containing enzymes is
striking and includes proteins of vital physiological signif-
icance involved in functions such as oxygen transport, cell
respiration, and DNA synthesis [11, 12]. Living organisms
were also forced to concurrently evolve protection systems
against highly damaging HO∙ radicals produced by the iron-
catalyzed conversion of superoxide and H
2
O
2
. To this aim, a
complex regulatory pathway formed by a variety of proteins
that bind, transport, and store iron has been developed, in
order to maintain an appropriate iron balance in both the
individual cells and the whole body [13, 14]. Over the last
years, the mechanisms by which iron homeostasis at the cel-
lular and organismal levels is regulated have been elucidated.
In this review, we have summarized recent advances in the
control of iron homeostasis and how changes in availability of
poorly liganded ferrous iron are related to ROS production.
Moreover, we propose that whenever the efficiency of the
network controlling iron balance is compromised, the role of
ROS switches from signaling to damage (Figure 1).
2. The IRE/IRP Regulatory Pathway Controls
Cellular Iron Homeostasis
The challenging task of maintaining intracellular iron levels
sufficient for essential cellular functions, including ROS-
dependent cell signaling, but as low as possible to avoid
ROS-mediated injury, is controlled at multiple steps but
primarily accomplished by iron regulatory proteins (IRP1 and
IRP2), which strictly control intracellular ironmetabolism by
posttranscriptionally regulating the coordinated expression
of proteins involved in iron utilization (e.g., erythroid 5
aminolevulinic acid synthase, mitochondrial aconitase, and
Drosophila succinate dehydrogenase), uptake (transferrin
receptor (TfR1) and divalentmetal transporter (DMT1)), stor-
age (H and L ferritin subunits), and export (ferroportin) [15,
16] (Figure 2). IRP1 and IRP2 recognize and bind conserved
25–30 nucleotides-long RNA stem-loop structures named
iron responsive elements (IREs) in the untranslated regions of
the mRNAs coding for these proteins. It has also been shown
that IRPs can bind the mRNAs for other proteins not directly
related to iron homeostasis [15, 16].
The activity of IRP1 and IRP2 is dictated by the size of
the cellular labile iron pool (LIP), a pool of iron in the low
𝜇M range bound to low molecular weight compounds like
citrate or glutathione [17], which is in continuous equilibrium
with the sites of iron utilization or storage. When cells are
iron deficient and thus the size of the LIP is shrunk, IRP1
and IRP2 bind to IREs located in the 3󸀠 region of transcripts
and stabilize the mRNA for TfR1 and DMT1, thus increasing
the uptake of both transferrin-bound and unbound iron.
At the same time, binding to 5󸀠 IRE impairs translation of
mRNAs for ferroportin, the only iron exporter, and ferritin,
which sequesters iron in a catalytically inactive form. This
coordinate regulation eventually expands the cellular LIP.
Conversely, when the LIP is large, the IRE-binding activity
of both IRPs is decreased, resulting in efficient translation of
ferritin and ferroportin mRNAs and lower stability of TfR1
and DMT1 mRNAs, ultimately enhancing iron storage and
release over uptake [15, 16] (Figure 2).
Both IRPs are homologous to the mitochondrial TCA
cycle enzyme aconitase that converts citrate to isocitrate using
an iron sulfur cluster (4Fe–4S) as a cofactor, but only IRP1
can assemble a cluster when sufficient iron is available, thus
functioning as cytosolic aconitase, which is the prevailing
form in most cells. Conversely, in conditions of iron defi-
ciency, the cluster is disassembled and the IRP1 apoform
binds IRE [15, 16]. IRP2 accumulates in iron-deficient cells
where it binds IRE motifs with affinity and specificity similar
to that of IRP1, whereas in iron-replete cells it is rapidly tar-
geted for proteasomal degradation by an E3 ubiquitin ligase
complex that comprises FBXL5, a recently identified protein
containing an hemerythrin-like domain that is involved in
its regulation according to iron (and oxygen) availability
[18]. Under conditions of iron scarcity, the assembly of the
di-iron center in the hemerythrin-like domain is impaired
and FBXL5 is polyubiquitinated and degraded by the pro-
teasome, thereby leading to IRP2 stabilization. Conversely,
when iron is abundant, FBXL5 levels in the cell increase
promoting IRP2 (and apo-IRP1) proteasomal degradation
[19, 20].
The respective role and importance of IRPs have been
revealed by studies involving gene deletion [21, 22]. Ablation
of both IRP1 and IRP2, which are ubiquitously expressed,
is early embryonic lethal whereas single knockout mice are
viable, indicating that the two IRPs can compensate for each
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Figure 2: Simplified model of IRP-dependent regulation of intracellular iron homeostasis. The IRE/IRP machinery posttranscriptionally
controls the expression of the major proteins of intracellular iron import (transferrin receptor, TfR1), export (ferroportin, Fpn), and storage
(ferritin, Ft). Under conditions of iron excess in the labile iron pool (LIP), IRPs lose their RNA-binding capacity, and hence TfR1 mRNA is
degraded (small arrow) while Fpn and Ft mRNAs are actively translated (big arrow and circle, resp.). The opposite occurs under conditions
of iron deficiency: IRP1 and IRP2 binding to iron responsive elements (IREs) stabilize TfR1 mRNA (big arrow) and prevent the translation of
Fpn and Ft mRNAs (small arrow and circle, resp.); this response increases iron availability.
other and confirming the in vitro data which suggested
essential but largely overlapping functions. However, early
studies did not show an apparent phenotype in IRP1 sin-
gle knockout mice, whereas hematopoietic defects and late
onset neurodegeneration were described in mice lacking
IRP2. These findings showing a dominant role for IRP2
in the regulation of iron homeostasis in mice were in line
with a study indicating that IRP2 is the major regulator
of intracellular iron metabolism in humans [23]. However,
recent results showed that IRP1 predominantly binds specific
IRE-containing mRNAs, such as those coding for erythroid
aminolevulinate synthase and hypoxia inducible factor 2𝛼
(HIF2𝛼) [24].
Although iron is the major regulator of the IRE/IRP
network, other signals and conditions can modulate the
activity of both IRPs, including oxygen tension and nitric
oxide (reviewed in [16]). Not surprisingly given the rela-
tionship between ROS and iron, IRPs are both targets and
modulators of free radical reactions and IRP activity is
altered under conditions of oxidative stress. Despite reports
showing IRP1 activation in cells exposed to H
2
O
2
, whichmay
be a phenomenon more correlated to the signaling role of
H
2
O
2
rather than to oxidative stress, it appears that IRP1
inactivation occurs in response to ROS both in vitro and
in vivo [15, 16]. Overall, since IRP2 is highly susceptible to
ROS-mediated downregulation, it is possible to conclude that
inhibition of IRP1 and IRP2 binding activity, with ensuing
ferritin induction and reduction of LIP, may represent a pro-
tective strategy to prevent amplification of oxidative injury
(discussed in [25]). The role of ferritin as an antioxidant
protein is underscored by the multiplicity of mechanisms
leading to its upregulation in response to oxidative challenge;
in fact, it has been demonstrated that stressful conditions
transcriptionally activate ferritin expression in various cell
types, and ferritin overexpression protects from oxidative
stress [26].
Readers can refer to recent excellent and comprehensive
reviews for specific aspects of the IRE/IRP regulatory network
[24, 27–29].
3. Conditions in Which Disruption of
Cellular Iron Homeostasis Leads to
Oxidative Damage
3.1. Neurodegenerative Disorders. Abundant evidence shows
that a number of neurodegenerative disorders are character-
ized by regional iron accumulation in particular areas of the
central and/or peripheral nervous systems [30, 31]. This is
often caused by cellular iron redistribution and may result
in iron-catalyzed Fenton chemistry. For instance, increased
iron levels in specific regions of the brain are a hallmark of
Parkinson disease [32].
Friedrich’s ataxia (FRDA) is a paradigmatic example
because the disruption of iron homeostasis in this disease has
been well defined [33]. FRDA, which is the most prevalent
form of hereditary ataxia in Caucasians, is characterized by
progressive degeneration of large sensory neurons in the
central and peripheral nervous systems leading to neuro-
logical impairment. In addition to neurological symptoms
like spinocerebellar and sensory ataxia, FRDA patients also
suffer from important nonneurological manifestations, in
particular hypertrophic cardiomyopathy. The disease results
from loss of function mutations (most often triplet expan-
sion) in the FXN gene that lead to decreased expression of
frataxin, a mitochondrial iron-binding protein that interacts
with proteins involved in the mitochondrial Fe-S cluster
biogenesis [34]. In patients, frataxin deficiency results in
disruption of Fe-S cluster biosynthesis, severe mitochondrial
iron overload, a hallmark of Fe-S defects, and increased
sensitivity to oxidative stress [35].
Although several studies provided evidence that ROS
generated through Fenton reaction play a role in FRDA,
the primary involvement and the importance of ROS in the
pathophysiology of FRDA are still debated [33]. However,
the protection afforded by mitochondrial ferritin, which has
a strong antioxidant role [36], in yeast, mammalian cells,
and fibroblasts from FRDA patients was accompanied by
reduced ROS level, thus strongly indicating the involvement
of toxic free radicals [37]. Since mitochondrial ferritin plays
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a protective role in several pathological conditions by seques-
tering iron [36], these data suggest that iron chelators are
of particular interest as therapeutic approaches for FRDA.
However, FRDA and other regional sideroses (i.e., iron
accumulation in particular tissues or cell compartments) will
require novel chelation modalities [38].
3.2. Role of Iron and ROS in Anthracycline Cardiotoxicity.
The role of iron in anthracycline cardiotoxicity is another
illuminating example of the complex interplay and synergism
between iron and free radicals as causative factors of apopto-
sis or other forms of cell damage. Doxorubicin (DOX) is an
antineoplastic drug of the anthracyclines family, which plays
a recognized key role in the chemotherapy for several types
of cancer. However, anthracyclines have established risks
of cardiotoxicity, as their chronic administration induces
cardiomyopathy and congestive heart failure [39]. This dose-
dependent side effect limits the clinical use of DOX in cancer
patients. Multiple mechanisms of cardiotoxicity induced by
DOX have been described, but activation of the mitochon-
drial intrinsic pathway of apoptosis seems to represent a
major response to anthracycline treatment.The development
of anthracycline-induced cardiomyopathy has been found to
depend on drug metabolism [40]; in fact, in addition to the
role of reductive activation of the quinone moiety of DOX
discussed below, a correlation exists between toxicity and
myocardial accumulation of anthracycline secondary alcohol
metabolites [39]. Conversely, anthracycline oxidative degra-
dationmay serve as a salvage pathway for diminishing the lev-
els and toxicity of DOX in cardiomyocytes (reviewed in [41]).
The involvement of iron inDOX-induced cardiac damage
is well established, and cardiotoxicity induced by DOX may
occur at lower cumulative doses under conditions of iron
overload [42]. The adverse role of iron has been suggested by
several lines of evidence: in particular, a number of studies
showed the protecting efficacy of iron chelators both in
patients and in animal models, while others demonstrated
that primary and secondary iron overload exacerbated the
cardiotoxic effects of the drug, but the underlying molecular
mechanisms remain to be fully understood (see [39, 41, 42]
for review). Iron has been proposed to act as a catalyst of
ROS formation in reactions primed by DOX. In fact, DOX
is a redox compound, as NAD(P)H reductases catalyze one-
electron reduction of the quinone moiety of the tetracycline
ring to the semiquinone free radical, which can regenerate the
parent quinone reacting with molecular oxygen. The latter
reaction generates O
2
− and its dismutation product H
2
O
2
,
which can then be transformed into the more potent HO∙ by
reactions catalyzed by iron. In turn, HO∙ can damage DNA
and proteins and initiate membrane lipid peroxidation, thus
leading to cardiomyocyte death [42, 43].
However, since antioxidants did not offer protection in
clinical settings, the apparently obvious explanation for the
aggravating role of iron in DOX cardiotoxicity based on
increased iron-catalyzed ROS formation has been called
into question [39, 41]. In line with this view, we showed
that DOX doses in the range of the plasma levels found
in patients undergoing chemotherapy were able to cause
apoptotic death of cardiac-derived H9c2 myocytes in the
absence of ROS production [44]. Moreover, we provided
evidence that activation of the HIF pathway contributes to
the cardioprotective effect of the iron chelator dexrazoxane,
thus suggesting that the protective capacity of iron chelators
against DOX toxicity may be mediated by mechanisms not
related to the prevention of ROS formation [45].
We also showed that anthracycline cardiotoxicity is
related to ROS-dependent and ROS-independent disruption
of cardiac iron homeostasis due to targeted interaction of
DOX with IRP1, which leads to a “null” IRP1 devoid of
both its functions and hence it is unable to sense iron levels
and to regulate iron homeostasis. Moreover, DOX triggers
IRP2 degradation, which may serve as a protective role by
favoring iron sequestration in newly formed ferritin [25,
46]. Indeed, it has been shown that ferritin is induced in
H9c2 cardiomyocytes [47] and mouse hearts [48] exposed
to DOX and protects cardiac cells against iron toxicity.
Moreover, ferritin H chain plays an important role in the
preventive effect of metformin against DOX cardiotoxicity
in isolated cardiomyocytes [49]. DOX treatment also results
in iron storage by inducing mechanisms leading to higher
accumulation of iron into ferritin [50]. Overall, these results
suggest that the role of iron in anthracycline-dependent
cardiotoxicity may extend beyond the formation of ROS.
On the other hand, recent results regarding mitochon-
drial ferritin (FtMt), a ferritin type particularly expressed
in mitochondria-rich tissues, including the heart, where
it prevents iron-mediated oxidative damage [51], reinforce
the idea that ROS are involved in the mechanisms linking
iron and anthracycline cardiotoxicity. FtMt expression was
induced in the heart of mice exposed to DOX [52], and FtMt-
deficient mice exposed to DOX are more sensitive to ROS-
mediated heart damage and death [53]. In addition,micewith
heart-specific deletion or overexpression of ABCB8, which
exports iron out of the mitochondria, were more sensitive or
resistant, respectively, to DOX cardiotoxicity [52].
The importance of methodological aspects introduces
some cautionary issues that should be taken into account
when considering the discrepancies reported above regard-
ing the pathophysiological relevance of iron-mediated ROS
production in DOX toxicity. In fact, one should keep in
mind that the model systems in which the mechanisms of
DOX cardiotoxicity have been characterized have inherent
limitations in representing the human chronic cardiomyopa-
thy. Moreover, the dual role of ROS in signaling events and
cell damage should be considered when evaluating if iron
contributes to chronic cardiomyopathy by mechanisms not
related to its ability to generate HO∙.
4. Systemic Iron Metabolism
Given the dual role of iron, elegant control mechanisms have
evolved to maintain appropriate body iron levels by means
of a complex network of transporters, storage molecules,
and regulators. Intestinal iron absorption and iron recycling
in reticuloendothelial cells are coordinately orchestrated in
order to maintain iron levels in the circulation adequate for
the needs of the various tissues and organs but insufficient to
activate dangerous ROS production [13, 14].
Oxidative Medicine and Cellular Longevity 5
Transferrin iron
Duodenum
Red blood cells
Liver
Hepcidin
Fpn
Reticuloendothelial cells
Hepcidin
Fpn
Fpn
Hepcidin
Figure 3: Hepcidin regulates transferrin-mediated body iron traffic. The interaction of hepcidin with ferroportin inhibits the flow of iron
into plasma and thereby regulates the transferrin-mediated distribution of iron in the body from sites of iron absorption (duodenum) and
recycling (reticuloendothelial cells in spleen and liver) to tissues where it is used (e.g., for the synthesis of hemoglobin in red blood cells) or
stored (e.g., liver).
The task of keeping circulating iron in a safe but readily
available form is performed by transferrin (Tf), a protein
synthesized and secreted by the liver that binds up to two
ferric iron atoms with high affinity and is the major iron
transport protein. Under physiological conditions, Tf-bound
iron is the main source of iron for the majority of tissues,
primarily for bone marrow erythroid precursors, which
consume iron for hemoglobin biosynthesis (Figure 3).
Tf incorporates iron coming from two major sources:
dietary iron (both inorganic and heme iron) absorbed in the
duodenum to compensate for daily iron loss and iron derived
from destruction of old and effete erythrocytes by reticuloen-
dothelial cells in the spleen and liver (Figure 3). After reduc-
tion by the reductaseDcytB, dietary iron is transported across
the apical membrane of absorptive epithelial cells by DMT1
[54]. In intestinal enterocytes, most iron is then exported to
the blood at the basolateral surface by ferroportin, assisted
by the function of oxidases (circulating ceruloplasmin and
membrane-bound hephaestin) that convert ferrous iron to
ferric iron and thus permit the incorporation of iron into Tf.
Although various transporters have been identified [54], the
mechanisms of intestinal uptake and release of heme iron are
less clearly understood, but the majority of heme is degraded
in the enterocytes and iron is released by ferroportin, as
ferroportin-deficient mice are not viable [55].
Spleen and liver macrophages specialized in recycling
iron obtained from the phagocytosis and destruction of
senescent erythrocytes are the main iron supplier for hemo-
globin synthesis. The major pathway of heme iron recy-
cling involves hemoglobin degradation by cytosolic heme
oxygenase-1 and export of heme-derived iron into the circu-
lation by ferroportin [56].
Recent studies in mice with disrupted IRP1 and/or IRP2
in the entire organismor specific tissues have shown that IRPs
are important regulators also of systemic homeostasis [22],
but hepcidin, a peptide hormone produced and secreted by
the liver, can be considered the key regulator of body iron
balance [57, 58].That hepcidin is most important regulator of
body iron homeostasis which is also indicated by a number
of studies showing that disruption of hepcidin regulation
is involved in a variety of disorders associated with iron
deficiency (e.g., anemia) or overload (e.g., siderosis). In
particular, inadequate hepcidin levels in relation to body iron
stores characterize most hereditary iron overload diseases
[59]. Hepcidin controls plasma iron concentration and body
iron balance by regulating the expression of ferroportin, the
only known cellular iron exporter (Figure 3). The binding of
hepcidin to ferroportin on the plasma membrane induces
its internalization and degradation, thereby blocking iron
release [60]. Hepcidin expression is regulated at multiple
levels: the expression of hepcidin is induced by iron overload,
inflammatory stimuli, or endoplasmic reticulum stress [57,
58, 61]; this mechanism stops the efflux of unwanted iron in
the circulation by negatively modulating iron absorption by
enterocytes, iron recycling by reticuloendothelial cells, and
iron mobilization from hepatic stores. Conversely, increased
erythropoietic activity under conditions of iron deficiency,
anemia, and hypoxia represses hepcidin, thereby leading to
higher iron availability for new erythrocytes synthesis [20,
62]. Among the positive regulators of hepcidin, iron exerts
its effect through the BMPs/SMAD dependent pathway,
while inflammatory cytokines, especially IL-6, activate the
JAK2-STAT3 signaling cascade. Erythroferrone, produced
by erythroid precursors in the marrow and the spleen in
response to erythropoietin, seems to be themajor inhibitor of
hepcidin production when erythropoiesis is stimulated [63].
4.1. Iron Overload Conditions. Two mechanisms protect the
cells from the damaging effects of excess body iron: the
partial saturation of Tf at the systemic level and the IRP-
dependent regulated expression of TfR1 at the cellular level.
Under normal conditions, Tf saturation is around 30% and
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Figure 4: Mechanisms of iron overload mediated tissue damage. Whenever the iron-binding capacity of transferrin (Tf) is exceeded, non-
transferrin-bound iron (NTBI) forms, penetrates into the cells, and undergoes redox cycling, ultimately leading to cell injury and organ
damage.
the protein can therefore bind excess iron entering the
circulation, thus functioning as a protective shield against
HO∙ production. However, under conditions of heavy sys-
temic iron overload (primarily due to insufficient hepcidin
production), the iron-binding capacity of Tf is exceeded,
andnon-transferrin-bound iron (NTBI) is formed (Figure 4).
Despite the downregulation of TfR1, cells become iron-
loaded because NTBI, that is, iron associated with various
low molecular weight plasma components, like citrate, phos-
phates, and proteins, lacks a regulated uptake system and
hence is able to penetrate into the cells [38]. The consequent
decrease in IRP binding activity leads to efficient ferritin
mRNA translation to promote iron storage, but ultimately
the high capacity of ferritin is exceeded as this unabated
flux of NTBI continues. NTBI is clearly involved in tissue
siderosis, but the incomplete characterization of the iron
species involved prevents a clear understanding of how it
enters the cell under different pathological conditions. NTBI
enters into cells mainly through divalent cation transporters
such asDMT1 andZIP14,which require previous reduction to
ferrous iron [64, 65] orCa2+ channels, either L-type orT-type,
particularly in cardiomyocytes [66]. NTBI toxicity within
cells derives from the fact that iron in the expanded LIP is
no longer protected from redox cycling; hence, it accelerates
the catalysis of reactions that produce HO∙, which then cause
lipid peroxidation and organelle damage and ultimately cell
death (Figure 4). In particular, mitochondria appear to be
primarily affected by iron-mediated HO∙ production. In fact,
it has been demonstrated that mitochondria rapidly acquire
NTBI, and this, along with their high generation of ROS
[67], props up oxidative damage. Apparently, the variety of
enzymatic and nonenzymatic antioxidant defense systems is
inadequate to prevent metal-catalyzed oxidative injury once
iron in the LIP is increased [66]. Although production of
hydroxyl radical and lipid peroxidation are important in the
initiation of iron overload pathology, additional mechanisms
involving apoptosis and fibrosis can account for its complex
pathophysiology that leads to organ failure [58].
The most important clinical conditions involving pri-
mary and secondary iron overload leading to iron-mediated
tissue damage are genetic hemochromatosis and transfu-
sional siderosis, respectively. Hereditary hemochromatosis
linked to mutations in HFE, a MHC class I-like protein
that is a necessary component of the iron-sensing machin-
ery controlling hepcidin expression, is the most common
genetic disease in Caucasians and presents a multisystem
involvement: although iron overload first affects the liver, in
hemochromatosis patients endocrine abnormalities, cardiac
problems, and arthropathy are also common [68]. Loss of
HFE function leads to inappropriately low hepcidin produc-
tion and unneeded iron release in the bloodstream from
the duodenum and reticuloendothelial system. Consequent
NTBI formation and iron deposition in parenchymal cells
lead to oxidative damage and determine the clinical features
of hemochromatosis [69].
Secondary iron overload is mainly observed in associa-
tion with transfusion-dependent diseases [70]. Since our
body lacks any regulated mechanism to effectively excrete
excess iron, long-term blood transfusion inescapably results
in iron overload in patients. Transfusional iron over-
load affects particularly patients with inherited hemoglo-
binopathies, such as 𝛽 thalassemia, which is the secondary
iron overload condition more closely linked to tissue iron
overload [71, 72]. However, the adverse effects of iron over-
load are also found in patients with a variety of conditions
(e.g., Blackfan-Diamond anemia, aplastic anemia, sideroblas-
tic anemia, myelodysplasia, etc.).
With continued transfusion, reticuloendothelial cells can
no longer safely store all the excess iron, which thus enters
the circulation in amounts that exceed the binding capacity
of Tf, and NTBI develops [69]. It should be noted that in
conditions such as 𝛽 thalassemia hepcidin levels are paradox-
ically low because erythropoiesis-dependent downregulation
prevails over the upregulation associated with body iron
levels; therefore, high intestinal iron absorption contributes
to iron overload [20, 62].While in hemochromatosis patients
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excess iron is removed by phlebotomy, the treatment of
transfusional iron overload is mainly based on iron chelation
therapy [61]. Iron chelators can be considered as antioxidants,
but not all the possible molecules able to bind iron can be
regarded as safe antioxidants. Since all the six iron atoms have
to be bound to the chelator to form a stable complex, incom-
plete iron-chelate complexes (e.g., iron-EDTA) can undergo
redox cycling and generate harmful free radicals. Therefore,
for efficient and safe scavenging of excess iron, chelating
molecules and/or dosages should be carefully evaluated to
raise the thermodynamic stability of the iron-ligand complex.
5. Conclusions
Presently, it is not completely clear as to why in some
conditions ROS are associated with cell damage and scav-
enging high ROS levels improves metabolic homeostasis,
whereas in other settings ROS exert signaling functions
important for essential cell activities. Possible explanations
for these distinct biological specificities of ROS action include
differences in the amount, sources, duration, and localization
of ROS production; in addition, certainly, the higher ROS
reactivity is, the greater toxicity is, while signaling capacity
is diminished. Therefore, H
2
O
2
, which is relatively stable
and diffusible, is indeed a mild oxidant but is suitable for
signaling. However, in the presence of ferrous iron, H
2
O
2
can generate the highly reactive and toxic HO∙. Therefore,
we propose that increased availability of iron not bound to
proteins specifically evolved to transport or store this essen-
tial metal can make the critical difference between the two
opposite functions of ROS. The view that iron plays a main
role in the scenario leading ROS to become signal or stress
agents is supported by the sophisticated systems regulating
intracellular and systemic iron homeostasis that we have
summarized in this review. Additional evidence indicating
the contribution of iron emerges from the number of studies
showing the occurrence of ROS-mediated tissue damage
whenever the control of iron metabolism is disrupted, con-
ditions of which we selectively highlighted a few illustrative
examples. Improved understanding of the complex interplay
between iron metabolism and redox homeostasis will clarify
these pathways and their relevance in pathophysiology. In
consideration of the disappointing results of antioxidant ther-
apy for a variety of diseases [73], targeting iron will possibly
represent a more advanced therapeutic approach aimed at
preventing the harmful effects of ROS while permitting their
physiological role in cell signaling.
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